Published in N Engl J Med on March 19, 2014
Comparative Effectiveness of FITs With Colonoscopy | NCT03264898
Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study. PLoS Med (2015) 1.74
Recommendations on screening for colorectal cancer in primary care. CMAJ (2016) 1.52
Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: a network meta-analysis. Gastrointest Endosc (2015) 1.51
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer. Obstet Gynecol (2014) 1.46
Potential of fecal microbiota for early-stage detection of colorectal cancer. Mol Syst Biol (2014) 1.44
Colorectal cancer screening: will non-invasive procedures triumph? Genome Med (2014) 1.40
Fecal occult blood versus DNA testing: indirect comparison in a colorectal cancer screening population. Clin Epidemiol (2017) 1.37
Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer. Gastroenterology (2015) 1.35
Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. Gastroenterology (2015) 1.24
Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening. J Natl Cancer Inst (2015) 1.10
Colorectal cancer. Nat Rev Dis Prim (2015) 1.07
Genetic pathways, prevention, and treatment of sporadic colorectal cancer. Oncoscience (2014) 1.07
Effect of Colonoscopy Outreach vs Fecal Immunochemical Test Outreach on Colorectal Cancer Screening Completion: A Randomized Clinical Trial. JAMA (2017) 1.05
Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia. Clin Cancer Res (2015) 1.03
Depletion of Abundant Sequences by Hybridization (DASH): using Cas9 to remove unwanted high-abundance species in sequencing libraries and molecular counting applications. Genome Biol (2016) 1.00
Reducing inequities in colorectal cancer screening in North America. J Carcinog (2014) 1.00
Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med (2014) 0.99
Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med (2014) 0.99
Colorectal cancer screening: tests, strategies, and perspectives. Front Public Health (2014) 0.99
CT colonography for population screening: ready for prime time? Dig Dis Sci (2014) 0.97
Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. Genome Med (2016) 0.97
The impact of screening on colorectal cancer mortality and incidence: has it really made a difference? Dig Dis Sci (2015) 0.96
Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med (2014) 0.94
Colorectal Cancer Biomarkers: Where Are We Now? Biomed Res Int (2015) 0.92
Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med (2014) 0.92
Molecular markers for colorectal cancer screening. Gut (2015) 0.92
Multi-target stool DNA test: a new high bar for noninvasive screening. Dig Dis Sci (2014) 0.91
Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med (2014) 0.91
The value of models in informing resource allocation in colorectal cancer screening: the case of the Netherlands. Gut (2015) 0.87
Fecal Microbiota Characteristics of Patients with Colorectal Adenoma Detected by Screening: A Population-based Study. EBioMedicine (2015) 0.87
New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice. Clin Cancer Res (2015) 0.87
Base resolution methylome profiling: considerations in platform selection, data preprocessing and analysis. Epigenomics (2015) 0.86
Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br J Cancer (2015) 0.86
Blood-based protein biomarker panel for the detection of colorectal cancer. PLoS One (2015) 0.85
Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol (2016) 0.85
Detection of endometrial cancer via molecular analysis of DNA collected with vaginal tampons. Gynecol Oncol (2015) 0.84
Simulation-guided DNA probe design for consistently ultraspecific hybridization. Nat Chem (2015) 0.84
Blood-based tests for colorectal cancer screening: do they threaten the survival of the FIT test? Dig Dis Sci (2015) 0.84
Fecal metabolomics: assay performance and association with colorectal cancer. Carcinogenesis (2014) 0.84
A Highly Predictive Model for Diagnosis of Colorectal Neoplasms Using Plasma MicroRNA: Improving Specificity and Sensitivity. Ann Surg (2016) 0.83
Fecal DNA testing for colorectal cancer screening: Molecular targets and perspectives. World J Gastrointest Oncol (2015) 0.82
Colorectal cancer screening and surveillance in the elderly: updates and controversies. Gut Liver (2015) 0.81
Spectrin repeat containing nuclear envelope 1 and forkhead box protein E1 are promising markers for the detection of colorectal cancer in blood. Cancer Prev Res (Phila) (2014) 0.81
Epigenetic therapy in gastrointestinal cancer: the right combination. Therap Adv Gastroenterol (2016) 0.81
Screening: Early alert. Nature (2015) 0.81
Test characteristics of faecal immunochemical tests (FIT) compared with optical colonoscopy. J Med Screen (2014) 0.81
Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC Cancer (2015) 0.81
Diagnostics and Epidemiology of Colorectal Cancer. Visc Med (2016) 0.81
Stool DNA and colorectal-cancer screening. N Engl J Med (2014) 0.81
Developments in Screening Tests and Strategies for Colorectal Cancer. Biomed Res Int (2015) 0.80
Early detection of sporadic pancreatic cancer: strategic map for innovation--a white paper. Pancreas (2015) 0.80
Cell-free nucleic acids as noninvasive biomarkers for colorectal cancer detection. Front Genet (2014) 0.80
Epigenetic mechanisms underlying the pathogenesis of neurogenetic diseases. Neurotherapeutics (2014) 0.80
Emerging stool-based and blood-based non-invasive DNA tests for colorectal cancer screening: the importance of cancer prevention in addition to cancer detection. Abdom Radiol (2016) 0.80
The Microbiome and Cancer: Is the 'Oncobiome' Mirage Real? Trends Cancer (2015) 0.80
Exploring Metabolic Profile Differences between Colorectal Polyp Patients and Controls Using Seemingly Unrelated Regression. J Proteome Res (2015) 0.79
DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model. Microbiome (2016) 0.79
Expression of young HERV-H loci in the course of colorectal carcinoma and correlation with molecular subtypes. Oncotarget (2015) 0.79
Rectal Optical Markers for In Vivo Risk Stratification of Premalignant Colorectal Lesions. Clin Cancer Res (2015) 0.79
Smoking status informs about the risk of advanced serrated polyps in a screening population. Endosc Int Open (2015) 0.79
Use of NCCN Guidelines, Other Guidelines, and Biomarkers for Colorectal Cancer Screening. J Natl Compr Canc Netw (2016) 0.79
Colonic mucosal fatty acid synthase as an early biomarker for colorectal neoplasia: modulation by obesity and gender. Cancer Epidemiol Biomarkers Prev (2014) 0.79
Systematic large-scale meta-analysis identifies a panel of two mRNAs as blood biomarkers for colorectal cancer detection. Oncotarget (2016) 0.78
The history of colorectal cancer screening: a personal perspective. Dig Dis Sci (2015) 0.78
Stool methylated DNA markers decrease following colorectal cancer resection--implications for surveillance. Dig Dis Sci (2014) 0.78
MAPRE1 as a Plasma Biomarker for Early-Stage Colorectal Cancer and Adenomas. Cancer Prev Res (Phila) (2015) 0.78
Biomarker-directed Targeted Therapy in Colorectal Cancer. J Dig Cancer Rep (2015) 0.78
Higher Order Chromatin Modulator Cohesin SA1 Is an Early Biomarker for Colon Carcinogenesis: Race-Specific Implications. Cancer Prev Res (Phila) (2016) 0.78
DNA Methylation and Mutation of Small Colonic Neoplasms in Ulcerative Colitis and Crohn's Colitis: Implications for Surveillance. Inflamm Bowel Dis (2016) 0.78
A Blood Test for Methylated BCAT1 and IKZF1 vs. a Fecal Immunochemical Test for Detection of Colorectal Neoplasia. Clin Transl Gastroenterol (2016) 0.78
Targeted proteomics for multiplexed verification of markers of colorectal tumorigenesis. Mol Cell Proteomics (2017) 0.78
Where does it FIT? The roles of fecal testing and colonoscopy in colorectal cancer screening. Cancer (2015) 0.78
Current noninvasive tests for colorectal cancer screening: An overview of colorectal cancer screening tests. World J Gastrointest Oncol (2016) 0.77
Advances in Fecal Tests for Colorectal Cancer Screening. Curr Treat Options Gastroenterol (2016) 0.77
Point-of-care testing in the diagnosis of gastrointestinal cancers: current technology and future directions. World J Gastroenterol (2015) 0.77
MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection. Oncotarget (2016) 0.77
Urinary PGE-M in colorectal cancer: predicting more than risk? Cancer Prev Res (Phila) (2014) 0.77
In persons at average risk, stool DNA tests had higher sensitivity than FIT for detecting colorectal cancer. Ann Intern Med (2014) 0.77
Fecal Recovery of Ingested Cellular DNA: Implications for Noninvasive Detection of Upper Gastrointestinal Neoplasms. Dig Dis Sci (2015) 0.77
Emerging technologies for studying DNA methylation for the molecular diagnosis of cancer. Expert Rev Mol Diagn (2015) 0.77
Colorectal cancer screening quality, cost and practice in an era of healthcare transformation. Dig Dis Sci (2014) 0.77
British Society of Gastroenterology position statement on serrated polyps in the colon and rectum. Gut (2017) 0.76
Estimating the effect of targeted screening strategies: an application to colonoscopy and colorectal cancer. Epidemiology (2017) 0.76
Choosing the optimal method in programmatic colorectal cancer screening: current evidence and controversies. Therap Adv Gastroenterol (2015) 0.76
Mutational profiles of different macroscopic subtypes of colorectal adenoma reveal distinct pathogenetic roles for KRAS, BRAF and PIK3CA. BMC Gastroenterol (2014) 0.76
Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease. J Thorac Oncol (2016) 0.76
Colorectal cancer screening: the time to act is now. BMC Med (2015) 0.76
Field Cancerization in Sporadic Colon Cancer. Gut Liver (2016) 0.76
Colonoscopy Surveillance after Colorectal Cancer Resection: Recommendations of the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol (2016) 0.76
Screening: Where does stool DNA testing FIT in the CRC screening menu? Nat Rev Clin Oncol (2014) 0.76
Recommendations for a step-wise comparative approach to the evaluation of new screening tests for colorectal cancer. Cancer (2016) 0.76
Colorectal cancer development and advances in screening. Clin Interv Aging (2016) 0.76
DNA methylation signatures in circulating cell-free DNA for the monitoring of at-risk populations progressing to lung cancer. EBioMedicine (2015) 0.76
The molecular pathogenesis of colorectal cancer and its potential application to colorectal cancer screening. Dig Dis Sci (2014) 0.76
Colonoscopy: the current king of the hill in the USA. Dig Dis Sci (2014) 0.75
Combined clinical and genetic testing algorithm for cervical cancer diagnosis. Clin Epigenetics (2016) 0.75
Analysis of RET promoter CpG island methylation using methylation-specific PCR (MSP), pyrosequencing, and methylation-sensitive high-resolution melting (MS-HRM): impact on stage II colon cancer patient outcome. Clin Epigenetics (2016) 0.75
Highly sensitive, non-invasive detection of colorectal cancer mutations using single molecule, third generation sequencing. Appl Transl Genom (2015) 0.75
Major milestones in translational oncology. BMC Med (2016) 0.75
Multiplex determination of serological signatures in the sera of colorectal cancer patients using hydrogel biochips. Cancer Med (2016) 0.75
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology (2008) 15.86
Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin (2008) 12.90
Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology (2012) 8.51
Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol (2002) 6.63
Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med (2014) 6.54
Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med (2004) 6.42
Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology (2005) 6.34
Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med (2012) 5.81
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res (2005) 5.68
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. Gastroenterology (2006) 4.57
Five-year risk of colorectal neoplasia after negative screening colonoscopy. N Engl J Med (2008) 4.55
Are physicians doing too much colonoscopy? A national survey of colorectal surveillance after polypectomy. Ann Intern Med (2004) 4.49
Intestinal inflammation and cancer. Gastroenterology (2011) 4.13
Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology (2003) 4.10
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology (2007) 3.94
Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst (2007) 3.80
Derivation and Validation of a Scoring System to Stratify Risk for Advanced Colorectal Neoplasia in Asymptomatic Adults: A Cross-sectional Study. Ann Intern Med (2015) 3.45
Using risk for advanced proximal colonic neoplasia to tailor endoscopic screening for colorectal cancer. Ann Intern Med (2003) 3.39
Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med (2009) 3.34
Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology (2002) 3.28
Use of a patient navigator to increase colorectal cancer screening in an urban neighborhood health clinic. J Urban Health (2005) 3.28
Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin (2006) 3.21
Results of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med (2002) 3.11
Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. JAMA (2002) 3.11
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
A national survey of primary care physicians' methods for screening for fecal occult blood. Ann Intern Med (2005) 3.01
Adequacy of reporting race/ethnicity in clinical trials in areas of health disparities. J Clin Epidemiol (2003) 2.94
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc (2007) 2.82
Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res (2007) 2.77
International variation in screening mammography interpretations in community-based programs. J Natl Cancer Inst (2003) 2.75
Prospective blinded evaluation of computed tomographic colonography for screen detection of colorectal polyps. Gastroenterology (2003) 2.74
Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med (2008) 2.74
Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med (2015) 2.71
Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev (2013) 2.56
Extracolonic findings at CT colonography: evaluation of prevalence and cost in a screening population. Gastroenterology (2003) 2.54
Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol (2006) 2.38
Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer (2007) 2.36
A novel antimicrobial and antithrombotic lock solution for hemodialysis catheters: a multi-center, controlled, randomized trial. Crit Care Med (2011) 2.36
Cancers complicating inflammatory bowel disease. N Engl J Med (2015) 2.33
AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.31
Improving colorectal cancer screening in primary care practice: innovative strategies and future directions. J Gen Intern Med (2007) 2.26
Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology (2012) 2.26
National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14-16, 2002. Gastrointest Endosc (2002) 2.20
Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut (2013) 2.17
Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med (2013) 2.15
Cancer in inflammatory bowel disease. World J Gastroenterol (2008) 2.12
Nonpolypoid neoplastic lesions of the colorectal mucosa. Gastrointest Endosc (2008) 2.09
AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.09
Colorectal cancer screening with CT colonography, colonoscopy, and double-contrast barium enema examination: prospective assessment of patient perceptions and preferences. Radiology (2003) 2.04
Data sources for measuring colorectal endoscopy use among Medicare enrollees. Cancer Epidemiol Biomarkers Prev (2007) 2.02
Variation in polyp detection rates at screening colonoscopy. Gastrointest Endosc (2009) 1.94
Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology (2006) 1.89
Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology (2011) 1.86
Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer (2005) 1.75
The incidence of colorectal cancer following a negative screening sigmoidoscopy: implications for screening interval. Gastroenterology (2004) 1.74
Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med (2014) 1.68
Highly methylated genes in colorectal neoplasia: implications for screening. Cancer Epidemiol Biomarkers Prev (2007) 1.67
Variation of adenoma prevalence by age, sex, race, and colon location in a large population: implications for screening and quality programs. Clin Gastroenterol Hepatol (2012) 1.65
Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol (2009) 1.63
Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst (2014) 1.61
Stool screening for colorectal cancer: molecular approaches. Gastroenterology (2005) 1.61
Tailoring colorectal cancer screening by considering risk of advanced proximal neoplasia. Am J Med (2012) 1.54
Principles of cancer screening: lessons from history and study design issues. Semin Oncol (2010) 1.52
Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. Clin Gastroenterol Hepatol (2013) 1.52
Change in body size and the risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev (2007) 1.49
Clinicopathologic features and treatment outcomes in Cronkhite-Canada syndrome: support for autoimmunity. Dig Dis Sci (2011) 1.43
Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med (2007) 1.40
Demographic, medical, and psychosocial correlates to CAM use among survivors of colorectal cancer. Support Care Cancer (2007) 1.40
A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol (2008) 1.40
DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem (2003) 1.35
Comparison of the relative sensitivity of CT colonography and double-contrast barium enema for screen detection of colorectal polyps. Clin Gastroenterol Hepatol (2004) 1.34
High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology (2008) 1.34
Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and US Multi-Society Task Force on Colorectal Cancer. CA Cancer J Clin (2006) 1.33
Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol (2013) 1.30
Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. Carcinogenesis (2007) 1.28
Biomarker studies: a call for a comprehensive biomarker study registry. Nat Rev Clin Oncol (2011) 1.26
Evaluation of claims, medical records, and self-report for measuring fecal occult blood testing among medicare enrollees in fee for service. Cancer Epidemiol Biomarkers Prev (2008) 1.24
A morphologic analysis of sessile serrated polyps observed during routine colonoscopy (with video). Gastrointest Endosc (2011) 1.22
Aspirin, NSAIDs, and colorectal cancer: possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev (2004) 1.22
Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med (2014) 1.22
Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates. Cancer (2011) 1.20
Alcohol types and sociodemographic characteristics as risk factors for Barrett's esophagus. Gastroenterology (2008) 1.19
The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol (2011) 1.19
The process to discover and develop biomarkers for cancer: a work in progress. J Natl Cancer Inst (2008) 1.19
Hereditary nonpolyposis colorectal cancer in young colorectal cancer patients: high-risk clinic versus population-based registry. Gastroenterology (2002) 1.16
Association of large serrated polyps with synchronous advanced colorectal neoplasia. Am J Gastroenterol (2009) 1.14
A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev (2006) 1.14
A prospective, blinded assessment of the impact of preoperative staging on the management of rectal cancer. Gastroenterology (2002) 1.14
Changing trends in the incidence, stage, survival, and screen-detection of colorectal cancer: a population-based study. Clin Gastroenterol Hepatol (2005) 1.13
Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applications. JAMA (2002) 1.11
How can polygenic inheritance be used in population screening for common diseases? Genet Med (2013) 1.10
Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study. Ann Intern Med (2016) 1.10
Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. Clin Chem (2009) 1.10